G56W1 in Women With Postmenopausal Osteoporosis

Summary

This study will assess the pharmacokinetics and safety and explore therapeutic effects with once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women with post-menopausal osteoporosis .The anticipated time on study treatment is 24 weeks, and the target sample size is 148 individuals.

Timeline

Start

2018-10-01

Primary completion

2020-05-31

Completion

2020-08-31

Drugs

Indications